Phase 3 trial opens comparing T-bren antibody-drug conjugate to chemo in HER2+ metastatic urothelial cancer
Trial opening · ClinicalTrials.gov · 2026-10-13. Number 5 in the UrologyWatch Top 5 for October 14, 2026.
A phase 3 trial (planned enrollment 520) will compare trastuzumab brengitecan (T-bren) to standard platinum-based chemotherapy in HER2-expressing metastatic urothelial carcinoma progressing after anti-PD-(L)1 therapy.
Why it matters: Tests a novel HER2-targeted ADC as a post-immunotherapy option in a molecularly defined subgroup of metastatic urothelial cancer.
Source: ClinicalTrials.gov
Loading today's edition…